Dermatology

At the Royal North Shore Hospital Department of Dermatology Clinical and Translational Medicine Laboratory, we focus on three key areas including clinical trials, clinical projects and translational studies.

It can take more than 30 years from the discovery of a new medicine in the laboratory to the approved use of that compound with a patient in a clinic. It can then be another decade before that medicine is widely adopted by the medical community.

Our research team accelerates this entire process in three important ways. Firstly, by being actively involved in clinical trials, we can offer our patients immediate access to the latest and most advanced medicines.

Secondly, we conduct clinical studies to improve our understanding of the use of existing and new medicines, alongside projects to improve the early diagnosis and recognition of diseases.

And lastly, we perform laboratory experiments, with a focus on clinical observation and human tissues to better understand the causes of these conditions.

Ultimately, this means we are able to contribute to the discovery of new and targeted therapies for all dermatological conditions.


Prof Gayle Fischer OAM A/Prof Gayle Fischer OAM

Associate Professor
Dermatology, Northern Clinical School
Head of Department

Professor Gayle Fischer is the Royal North Shore Hospital Head of Department of Dermatology, and an Associate Professor at the University of Sydney, Discipline of Dermatology. Her research interests are vulval disease, paediatric dermatology and medical education. She runs a vulval disease and paediatric dermatology service at Royal North Shore Hospital. She has a 20-year career in researching and publishing on the subject of paediatric and vulval disease.

 

Dr Emma Smith PhD - Clinical Trials Coordinator

Melissa Franklin - Clinical Nurse Consultant

Erin Mewton - Transitional Nurse Practitioner

Dr Isobel Pye – Research Fellow

Clinical Trials:

Clinical trials conducted at our site are part of international multi-centre clinical trials. All of the trials are aiming to bring the latest and most advanced therapies to our patients. We mainly conduct phase 3 clinical trials as we believe that it is a stage that is most beneficial for our volunteer participants (patients). To enquire about any of our existing or upcoming clinical trials, please contact our Clinical Trials Coordinator, Dr Emma Smith, PhD: Emma.Smith2@health.nsw.gov.au

Current Clinical Trials:

1. M16-047 – Phase 3, Closed to recruitment, Following-up

Moderate to Severe Atopic Dermatitis: Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects

2. HS0005 – Phase 3, Closed to recruitment, Following-up

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

3. HS0004 – Phase 3, Closing-out in September 2022

A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

4. B7451015 – Phase 3, Closed to recruitment, Following-up

A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, with or without Topical Medications, Administered to Subjects Aged 12 Years And Older with Moderate to Severe Atopic Dermatitis

5. B7451064 – Phase 3, Closed to recruitment, Following-up

Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults with Moderate to Severe Atopic Dermatitis

Translational Laboratory:

The purpose of the Royal North Shore Hospital Department of Dermatology Translational Medicine Laboratory is to discover and refine better and accessible therapies through clinically relevant laboratory studies. We aim to be the premier laboratory for dermatology translational studies and for dermatological clinician-scientists to work globally.

We hope that within our lifetimes we will see targeted therapies for all dermatological conditions. We are well placed to achieve this given our talented team, our access to state of the art equipment within the Kolling Institute and the University of Sydney, and our emphasis on clinical observation.

Current Translational Projects:

  1. Cellular and molecular pathophysiology of chronic vulvovaginal candidiasis (CVVC).
    The lifetime risk of a woman developing CVVC is as high as 5%. CVVC is continuous and unremitting, and its causes are poorly understood. With our clinical observation that post-menopausal women who have commenced hormone replacement therapy (HRT) are significantly more likely to develop CVVC (49% vs 1%), we are investigating the intrinsic cellular, molecular, and proteomic changes that occur during HRT, to understand why these women are at a higher risk of developing chronic vulvovaginal candidiasis

  2. Targeting synaptic gating with piloerection and frisson to ameliorate pruritus.
    Pruritus (itch) is the flagship symptom of many dermatological, oncological, and chronic systemic conditions, however unlike pain, there are currently no targeted therapies for pruritus. There are both central and peripheral, inflammatory and neurogenic, mediators of pruritus, and we have observed clinically that patients who experience frisson-associated goosebumps no longer have itch symptoms. We aim to determine how to pharmacologically target piloerection and frisson to treat pruritus.

To enquire about any of our existing or upcoming translational studies, please contact our Research Fellow: geoffrey.lee@health.nsw.gov.au

Dermatology related information

Events, News and Seminars

Recognition for research excellence

Recognition for research excellence

Congratulations to Professor David Hunter who’s received a prestigious University of Sydney Vice Ch..... Read more

Category: Awards, New Treatment

Northern Sydney leading the way with arthritis research and clinical care

Northern Sydney leading the way with arthritis research and clinical care

The latest exciting research into musculoskeletal disease has been unveiled during the inaugural No..... Read more

Category: New Treatment